Brief: Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
22/05/2024 13:18
May 22 (Reuters) - Adlai Nortye Ltd ANL.O :
* ADLAI NORTYE ANNOUNCES FIRST PATIENT DOSED IN RANDOMIZED
PHASE
II CLINICAL TRIAL OF PALUPIPRANT (AN0025) FOR THE TREATMENT OF
LOCALLY ADVANCED RECTAL CANCER WITH RADIATION THERAPY
Source text for Eikon: ID:nGNX59m7HV
Further company coverage: ANL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adlai Nortye
See all newsAdvisory: Alerts wrongly tagged to Merck & Co withdrawn
Brief: Adlai Nortye Appoints Christopher Liu, Pharmd, As Head Of Investor Relations And Public Relations
Brief: Adlai Nortye Announces Clinical Trial Notification Submission And Hrec Approval
Brief: Adlai Nortye Files For Mixed Shelf Offering Of Up To $600 Million
U.S. STOCKS ON THE MOVE-Netflix, J.B. Hunt, Arxis